Literature DB >> 15201966

Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia.

Chise Matsushita1, Yang Yang, Seisho Takeuchi, Masahide Matsushita, Jacques J M Van Dongen, Tomasz Szczepanski, Claus R Bartram, Hiromi Seo, H Phillip Koeffler, Hirokuni Taguchi.   

Abstract

Methylation profile was analyzed in nine cases of relapsed childhood acute lymphoblastic leukemia (ALL) for p14, p15, p16, Rb, MGMT, APC, hMLH1, RARbeta, RIZ, DAPK, and FHIT genes by using methylation specific polymerase chain reaction (MSP) analysis. Frequency of methylation in each gene was: MGMT, 56%; RARbeta, 44%; and p16, 22%, respectively. None of the p14, p15, Rb, APC, hMLH1, RIZ, DAPK, and FHIT genes were hypermethylated. Five (56%) of 9 cases showed methylation of at least one gene. All of the samples with hypermethylation in p16 and MGMT gene at relapse, had already acquired the change at the time of initial diagnosis. Interestingly, three of 4 cases with RARbeta gene methylation at relapse did not have methylation of this gene at the time of initial presentation. These results suggest that hypermethylation might be involved in the relapse of childhood ALL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201966

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  FHIT promoter DNA methylation and expression analysis in childhood acute lymphoblastic leukemia.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Simin Sadeghi-Bojd; Mohsen Taheri
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

2.  Gravin gene expression in acute myeloid leukemia.

Authors:  Mohamed R Mostafa; Raida S Yahia; Hanaa M Abd El Messih; Eman El-Sisy; Doaa M El Ghannam
Journal:  Med Oncol       Date:  2013-03-31       Impact factor: 3.064

3.  Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia.

Authors:  Seisho Takeuchi; Masahide Matsushita; Martin Zimmermann; Takayuki Ikezoe; Naoki Komatsu; Taku Seriu; Martin Schrappe; Claus R Bartram; H Phillip Koeffler
Journal:  Leuk Res       Date:  2011-05-17       Impact factor: 3.156

4.  Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

Authors:  Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter C Adamson; Ashish M Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

5.  DNA methylation of the RIZ1 tumor suppressor gene plays an important role in the tumorigenesis of cervical cancer.

Authors:  H Y Cheng; Y Gao; Ge Lou
Journal:  Eur J Med Res       Date:  2010-01-29       Impact factor: 2.175

6.  Methylation of the Phospholipase A2 Receptor 1 Promoter Region in Childhood B Cell Acute Lymphoblastic Leukaemia.

Authors:  Markus Friedemann; Katharina Gutewort; Dana Thiem; Brit Nacke; Carsten Jandeck; Björn Sönke Lange; Olga Sukocheva; Meinolf Suttorp; Mario Menschikowski
Journal:  Sci Rep       Date:  2020-06-03       Impact factor: 4.379

Review 7.  Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia.

Authors:  Narges Aberuyi; Soheila Rahgozar; Elaheh Sadat Ghodousi; Kamran Ghaedi
Journal:  Front Oncol       Date:  2020-01-17       Impact factor: 6.244

Review 8.  Genetics and epigenetics of pediatric leukemia in the era of precision medicine.

Authors:  Kristie N Ramos; Irma N Ramos; Yi Zeng; Kenneth S Ramos
Journal:  F1000Res       Date:  2018-07-18

Review 9.  Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia.

Authors:  Huan Xu; Hui Yu; Runming Jin; Xiaoyan Wu; Hongbo Chen
Journal:  Cells       Date:  2021-11-29       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.